1. Home
  2. VNO vs DFTX Comparison

VNO vs DFTX Comparison

Compare VNO & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vornado Realty Trust

VNO

Vornado Realty Trust

SELL

Current Price

$34.72

Market Cap

6.3B

Sector

Real Estate

ML Signal

SELL

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

SELL

Current Price

$30.17

Market Cap

5.9B

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
VNO
DFTX
Founded
1946
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.9B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
VNO
DFTX
Price
$34.72
$30.17
Analyst Decision
Hold
Strong Buy
Analyst Count
13
19
Target Price
$39.15
★ $72.78
AVG Volume (30 Days)
1.3M
★ 1.6M
Earning Date
11-02-2026
11-09-2026
Dividend Yield
★ 2.13%
N/A
EPS Growth
★ 10400.00
N/A
EPS
★ N/A
N/A
Revenue
★ $1,810,425,000.00
N/A
Revenue This Year
$0.94
N/A
Revenue Next Year
$7.23
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 1.27
N/A
52 Week Low
$24.57
$14.62
52 Week High
$41.60
$49.70

Technical Indicators

Market Signals
Indicator
VNO
DFTX
Relative Strength Index (RSI) 48.05 37.55
Support Level $33.84 $20.43
Resistance Level $36.78 $38.59
Average True Range (ATR) 1.14 2.10
MACD -0.03 -0.21
Stochastic Oscillator 27.17 3.34

Price Performance

Historical Comparison
VNO
DFTX

About VNO Vornado Realty Trust

Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: